AI Article Synopsis
- Recent studies indicate a rising number of anticancer drugs approved for patients with blood-related cancers, but there's limited data on the risk of hepatitis B virus reactivation (HBV-R) in these patients.
- In a study of 845 patients, 30.5% were found at risk for HBV-R, with a low overall incidence of 2.1% in those with past HBV infections.
- The findings suggest that most cases of HBV-R are preventable and manageable, indicating that patients with HBV infection can still receive novel anticancer treatments without significant risk.
Article Abstract
Background: More and more novel anticancer drugs have been approved for patients with hematological malignancies in recent years, but HBV reactivation (HBV-R) data in this population is very scarce. This study aimed to evaluated HBV-R risk in patients with hematological malignancies receiving novel anticancer drugs.
Methods: HBV markers and serum HBV DNA levels of patients with hematological malignancies receiving novel anticancer drugs in a tertiary cancer hospital were retrospectively collected. HBV-R risk in the whole cohort and subgroups was described. The relevant literature was reviewed to make a pooled analysis.
Results: Of 845 patients receiving novel anticancer drugs, 258 (30.5%) were considered at risk for HBV-R. The median duration of exposure to novel drugs was 5.6 (0.1-67.6) months. The incidence of HBV-R was 2.1% in patients with past HBV infection without prophylactic antiviral treatment (PAT) and 1.2% in all patients at risk of HBV-R. In a pooled analysis of 11 studies with 464 patients, the incidence of HBV-R was 2.4% (95% CI: 1.3-4.2) in all at-risk patients receiving novel anticancer drugs and 0.6% (95% CI: 0.03-3.5) in patients with anticancer drugs plus PAT. The incidence of death due to HBV-R was 0.4% (95% CI: 0.1-1.6) in all at-risk patients and 18.2% (95% CI: 3.2-47.7) in patients with HBV-R.
Conclusion: Most episodes of HBV-R are preventable, and most cases with HBV-R are manageable. We recommend that novel anticancer drugs should not be intentionally avoided when treating cancer patients with HBV infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jmii.2023.04.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Network pharmacology-integrated molecular modeling analysis of L. (agarwood) essential oil phytocompounds.
In Silico Pharmacol
December 2024
Agro-Technology and Rural Development Division, CSIR-North East Institute of Science and Technology, Jorhat, Assam India.
A network pharmacology approach was used to construct comprehensive pharmacological networks, elucidating the interactions between agarwood compounds and key biological targets associated with cancer pathways. We have employed a combination of network pharmacology, molecular docking and molecular dynamics to unravel agarwood plants' active components and potential mechanisms. Reported 23 molecules were collected from the agarwood plants and considered to identify molecular targets.
View Article and Find Full Text PDFBiological evaluation of trans-2,3-dihydrofuro[3,2-c]coumarins as potential cathepsin inhibitors and anticancer agents.
J Biomater Sci Polym Ed
December 2024
Department of Chemistry, Chaudhary Bansi Lal University, Bhiwani, Haryana, India.
Novel trans-2,3-dihydrofuro[3,2-c]coumarins were synthesized and assessed for their inhibition potential against cysteine proteases: cathepsin B, H and L which are the possible targets for anticancer activity. In general, the coumarin derivatives were found to be exceptional inhibitors against this class of enzymes. On the basis of molecular modeling data and structure-activity relationships, their inhibition patterns are also discussed.
View Article and Find Full Text PDFFast detection of protein kinase B in chrysin treated colorectal cancer cells using a novel multicore microfiber biosensor.
Commun Eng
December 2024
State Key Laboratory of Information Photonics and Optical Communications, Beijing University of Posts and Telecommunications, Beijing, China.
Rapid and accurate determination of target proteins in cells provide essential diagnostic information for early detection of diseases, evaluation of drug responses, and the study of pathophysiological mechanisms. Traditional Western blotting method has been used for the determination, but it is complex, time-consuming, and semi-quantitative. Here, a tapered seven-core fiber (TSCF) biosensor was designed and fabricated.
View Article and Find Full Text PDFEnhancing glioblastoma therapy via intranasal administration of highly potent cell-penetrating peptide decorated nanoparticles.
J Control Release
December 2024
Department of Global Innovative Drugs, The Graduate School of Chung-Ang University, 221 Heukseok-dong, Dongjak-gu, Seoul 06974, Republic of Korea; College of Pharmacy, Chung-Ang University, 221 Heukseok-dong, Dongjak-gu, Seoul 06974, Republic of Korea. Electronic address:
Glioblastoma multiforme (GBM) is a devastating primary tumor of the central nervous system with a significantly poor prognosis. The primary challenge in treating GBM lies in the restrictive nature of the blood-brain barrier (BBB), impeding effective drug delivery to the brain. In this study, intranasal polymeric micelles encapsulating a quercetin-etoposide combination were developed to induce synergistic apoptotic effects and enhance direct drug delivery to the brain.
View Article and Find Full Text PDFAdvances in the selective c-MET kinase inhibitors: Application of fused [5,6]-Bicyclic nitrogen-containing cores for anticancer drug design.
Eur J Med Chem
December 2024
Department of Medicinal Chemistry, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran. Electronic address:
Over the past two decades, small molecules bearing [5,6]-bicyclic nitrogen-containing cores have emerged as one of the most extensively studied structures for the development of selective c-MET kinase inhibitors. Structure-activity relationship (SAR) studies have demonstrated that modifying these cores can significantly impact the biological properties of c-MET inhibitors, including safety/toxicity, potency, and metabolic stability. For example, although c-MET kinase inhibitors containing the [1,2,4]triazolo[4,3-b][1,2,4]triazine scaffold (core P) exhibit high inhibitory potency, they often face challenges due to metabolic stability defects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!